2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.
Naiyer A. Rizvi, MD, Price Family Professor of Medicine, director, Thoracic Oncology, co-director, Cancer Immunotherapy, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, research director, Price Family Comprehensive Center for Chest Care, NewYork-Presbyterian Hospital, discusses treatment approaches in non–small cell lung cancer (NSCLC).
Therapy for patients with NSCLC should be individualized and selected based on molecular abnormalities and PD-L1 status, says Rizvi.
However, patients with high PD-L1 expression and an EGFR mutation should receive targeted therapy rather than immunotherapy as oncogenic drivers are preferred to PD-L1 status, Rizvi explains.
Moreover, in an era where numerous plasma-based assays are receiving regulatory approval, molecular data should be thoroughly evaluated to inform treatment decisions before they are made, Rizvi concludes.